• 1
    Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30 positive cutaneous T-cell lymphoma. Blood. 2003; 101: 14871493.
  • 2
    Dummer R. CTCL—a tumour of skin homing T-cells. Exp Dermatol. 2002; 11: 483484.
  • 3
    Wollina U, Graefe T, Feldrappe S, et al. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J Cancer Res Clin Oncol. 2002; 128: 103110.
  • 4
    Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas. A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997; 90: 354371.
  • 5
    Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sèzary syndrome. Blood. 1996; 88: 23852409.
  • 6
    Van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136: 504510.
  • 7
    Bunn PA Jr., Hoffmann SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sèzary syndrome). Ann Intern Med. 1994; 121: 592602.
  • 8
    Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54 (Suppl 4): 17.
  • 9
    Nair R, Ramakrishnan G, Nair NN, et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphomas. Cancer. 1998; 82: 22822288.
  • 10
    Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 2734.
  • 11
    Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev. 2002; 28 (Suppl A): 711.
  • 12
    Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol. 2000; 42: 4046.
  • 13
    Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol. 2001; 127: 128134.
  • 14
    Tsatalas C, Martinis G, Margaritis D, et al. Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. J Eur Acad Dermatol Venereol. 2003; 17: 8082.
  • 15
    EEC. Good clinical practice for trials on medicinal products in the European Community. 11/3976/88-EN. Brussels: European Commission, 1991.
  • 16
    Vonderheit EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002; 46: 95106.
  • 17
    Kerl H, Sterry W. Classification and staging. In: BurgG, SterryW, editors. EORTC/BMFT Cutaneous Lymphoma Project Group: recommendations for staging and therapy of cutaneous lymphomas. Berlin: Springer, 1987: 110.
  • 18
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 12441253.
  • 19
    Seegenschmiedt MH. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol. 1998; 174 (Suppl 3): 2529.
  • 20
    Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000; 136: 14751480.
  • 21
    Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997; 54 (Suppl 4): 3035.
  • 22
    Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000; 11: 10291033.
  • 23
    Lorincz A. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet. 1996; 347: 871876.
  • 24
    Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998; 31: 583588.
  • 25
    Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996; 35: 573579.
  • 26
    Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86: 13681376.
  • 27
    Ho AD, Suciu S, Stryckmans P, et al. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Semin Oncol. 2000; 27 (Suppl 5): 5257.
  • 28
    Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestation. J Clin Oncol. 1999; 17: 31173121.
  • 29
    Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntington). 2000; 14 (Suppl 2): 3740.
  • 30
    Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000; 18: 26032606.
  • 31
    Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Tagretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001; 137: 649652.
  • 32
    Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phase II–III trial results. J Clin Oncol. 2001; 19: 24562471.
  • 33
    Waterhouse DN, Tardi PG, Mayer LD, Bally MP. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety. 2001; 24: 903920.
  • 34
    Working PK, Dayan AD. Pharmacological-toxicological expert report: Caelyx® (Stealth® liposomal doxorubicin HCl). Hum Exp Toxicol. 1996; 15: 752785.
  • 35
    Stewart JSW, Jablonowski H, Goebel F-D, et al. Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998; 16: 683691.
  • 36
    Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997; 54 (Suppl 4): 2229.
  • 37
    Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst. 1995; 87: 15561557.
  • 38
    Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, von Roenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995; 75: 21692173.
  • 39
    Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998; 4: 15671571.
  • 40
    Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999; 44: 303306.